Possible reasons for why a new study could not replicate our finding that the serotonin reuptake inhibitor citalopram decreased amyloid b concentrations in the cerebrospinal fluid of healthy volunteers.
of citalopram may explain our original results regarding the Abmodulating effect of citalopram. We believe, however, that two key methodological differences between the two studies (both noted by Emilsson et al. in their Letter) are more likely to explain the discrepancies in the findings.
These methodological differences relate to drug dose and timing of CSF sampling. Escitalopram has a half-life of about 28 hours (3). Consequently, given that Emilsson et al. gave the first dose of escitalopram 27 hours before CSF sampling, the drug concentration was reduced by 50% by the time of CSF sampling. Further, based on kinetic studies, it takes 6 hours after amyloid precursor protein (APP) is cleaved for changes in Ab to be detected in the CSF (4, 5) . Therefore, sampling CSF at 4 hours after the second drug dose means that the impact of that dose would not yet be present in the CSF. We think the study of (A) Young 3-to 4-month-old APP/PS1 hemizygous mice (pre-plaque) were implanted with unilateral microdialysis probes into the hippocampus [as described in (6)]. Baseline ISF Ab concentrations were established in each mouse for 7.5 hours, and then mice were administered a single dose of either vehicle [phosphate-buffered saline (PBS)], escitalopram (5 mg/kg), or citalopram (10 mg/kg) intraperitoneally (i.p.). ISF Ab was measured every 60 min for an additional 24 hours. The citalopram data are from a previously published study (6) , and the escitalopram data are from new studies using identical methods. Using a two-way analysis of variance (ANOVA) with repeated measures and Bonferroni correction for multiple comparisons, there was a significant difference between the drug treatment groups compared to vehicle; ***P < 0.001. (B) By hours 22 to 24 after drug dosing, there was a 16.0 ± 6.4% (*P = 0.03, n = 6) and a 26.0 ± 5.4% (*P = 0.0013, n = 4) decrease in ISF Ab with escitalopram and citalopram, respectively, compared to vehicle-treated mice (n = 6) (oneway ANOVA compared to vehicle; mean ± SEM). ns, not significant.
would have been (taking into account that escitalopram has twice the effect on serotonin reuptake inhibition as citalopram). This considerable difference in drug doses between the two studies could account for the lack of effect on CSF Ab reported in the Emilsson et al. Letter (1) .
We have also conducted parallel studies in mouse models of AD. To date, we have tested five SSRIs (6) for their effect on Ab concentrations in the brain ISF of APP transgenic and wild-type mice. In all cases, the SSRIs reduced ISF Ab by 15 to 30%. We have now also tested the Ab-lowering effect of escitalopram using a single dose of escitalopram in young APP/PS1 +/− mice. We found that, similar to the other SSRIs, there was a 16% reduction in ISF Ab by 24 hours after dosing (P = 0.03, n = 6) compared to vehicle (n = 6) (Fig. 1) . In previous work (6) , citalopram administered at 10 mg/kg also reduced ISF Ab concentrations in mice by 26% (P = 0.001, n = 4) (Fig. 1) . Citalopram and escitalopram were administered at comparable active-form doses to the APPswe/PS1dE9 hemizygous mice, and there was no significant difference between these two drugs (P = 0.302) regarding their effects on ISF Ab. That said, the effect of escitalopram on ISF Ab was not as robust as the effect of citalopram, suggesting that half a dose of escitalopram may not be quite as effective as citalopram in lowering Ab. Importantly, direct infusion of serotonin into the mouse brain also mimicked the effects of the SSRIs (6) . These data support our interpretation that increased serotonin signaling suppresses brain Ab production, as opposed to an off-target effect of citalopram or one of the drug's metabolites. We hope that future studies will define the signaling pathways that link serotonin receptors to Ab metabolism, providing more confidence in the mechanism underlying this phenomenon.
In summary, although Emilsson and colleagues present interesting findings in their Letter, differences in sampling times and drug dosing between their study and ours make it difficult to compare the two sets of results. Additional studies of the effects of SSRIs on Ab in humans are needed, and especially studies that use higher doses of escitalopram and better CSF sampling methods, which would enable assaying of the maximal CSF concentrations of the drug.
